Cohort study of patients with initially unresectable pancreatic cancer in whom conversion surgery is planned after FOLFIRINOX or gemcitabine plus nab-paclitaxel therapy
Not Applicable
- Conditions
- nresectable pancreatic cancer
- Registration Number
- JPRN-UMIN000035668
- Lead Sponsor
- Federation of Asian Clinical Oncology (FACO)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 360
Inclusion Criteria
Not provided
Exclusion Criteria
1. Borderline resectable disease by NCCN Guidelines Ver 2.2018 is excluded in this study. Solid tumor contact with the CA >180 degrees is classified to unrsectable. 2. Recurrent disease 3. Response to chemotherapy according to RECIST ver 1.1 was PD 4. Heavy ion radiotherapy or proton beam therapy performed before laparotomy 5. Diagnosed as unresectable disease by examination laparoscopic when was intented to conversion surgery 6. Resection of metastatic lesions at conversion surgery. However, patients can be registered unless they are pathologically demonstrated to have cancer after dissection of the 16th lymph node or hepatectomy. 7. Peritoneal lavage cytology positive
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival from the day when resection was considered to be possible (day of examination)
- Secondary Outcome Measures
Name Time Method Relapse-free survival, post-resection survival, mode of relapse, presence or absence of hospital death, and surgery-related complications